SPX3,998.84-72.86 -1.79%
DIA340.03-4.71 -1.37%
IXIC11,239.94-221.56 -1.93%

CORRECTED: JP Morgan Maintains Neutral on ACADIA Pharmaceuticals, Lowers Price Target to $17 - Rating Updated

Benzinga · 11/15/2022 14:51

CORRECTED: JP Morgan analyst Tessa Romero maintains ACADIA Pharmaceuticals (NASDAQ:ACAD) with a Neutral and lowers the price target from $19 to $17, rating updated.